1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Principia taps Series A tranche to arm warheads for covalent drug IND

 
• By Mandy Jackson

Principia Biopharma will use $12.5 million from the second tranche of a tiered Series A round totaling $36.3 million to file an investigational new drug (IND) application with the US FDA in 2013 for its first covalent drug.

Principia Biopharma will use $12.5 million from the second tranche of a tiered Series A round totaling $36.3 million to file an investigational new drug (IND) application with the US FDA in 2013 for its first covalent drug.

The San Francisco-based company is developing compounds that form reversible covalent bonds with targeted molecules so that the oral drugs inhibit proteins associated with autoimmune diseases and cancer, while causing fewer off-target side

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.